Drugs designed to treat diabetes and repurposed as miracle diet aids have become popular on TikTok and in Hollywood. The rapid weight loss achieved with these weekly injectables has impressed many, showcasing their newly slim figures.
But what exactly are these drugs, how do they work, and what was their original purpose? Let’s delve into the trio of Ozempic, Wegovy, and Mounjaro.
Ozempic gained significant attention in 2022, with reports suggesting it was the go-to injectable drug for weight loss in LA. Initially used by celebrities and the elite, its popularity soared. The generic name for Ozempic is semaglutide, which is the same as Wegovy, a weight loss drug licensed in the UK and available on the NHS. Wegovy has a higher dosage specifically designed for weight loss, while Ozempic was initially developed as a treatment for diabetes.
Mounjaro, also known as tirzepatide, is the new player in the market. Like Ozempic and Wegovy, it suppresses appetite and prolongs the digestion process, leading to weight loss as long as the medication is continued. In 2022, the FDA fast-tracked Mounjaro’s approval to treat obesity after showing significant weight loss results. It was set to be available in the UK through various healthcare services, but there have been delays in its rollout.
These drugs, originally developed for type 2 diabetes, function by lowering blood sugar levels through increased insulin production and preventing excessive sugar release by the liver. They also aid in weight loss by mimicking the hormone GLP-1 to manage hunger and slow digestion. Tirzepatide, specifically, mimics GIP in addition to GLP-1, resulting in weight loss of up to 20% in clinical trials.
While these drugs offer promising weight loss results, they come with side effects such as nausea, vomiting, and diarrhea, leading some to discontinue use. Serious risks include kidney failure, pancreatitis, and thyroid cancer. Additionally, sudden weight loss can cause facial aging, a phenomenon known as «Ozempic face.»
Research has shown that these weight loss injections may reduce the risk of obesity-related cancers by nearly half. However, further studies are needed to ensure they do not increase the risk of non-obesity-related cancers.
In the UK, an estimated 1.5 million people are using weight loss injections, primarily through private means. While Ozempic is available for type 2 diabetes patients, Wegovy and Mounjaro are accessible to NHS patients through specialized weight management services, although there have been delays in their distribution.
In conclusion, while these drugs offer significant weight loss benefits, potential users should be aware of the associated risks and side effects. It is essential to consult with healthcare professionals before starting any weight loss treatment regimen.
SOURCE